logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10689362 B1

PDFFull Text
Date of Patent:
Jun. 23, 2020

Filed:

Oct. 09, 2017

Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors

Applicant:

Development Center for Biotechnology, Taipei, TW;

Inventors:

Shao-Zheng Peng, Taipei, TW;

Chu-Bin Liao, Taipei, TW;

Hung-Kai Chen, Taipei, TW;

Chen-Hsuan Ho, Taipei, TW;

Hung-Jyun Huang, Taipei, TW;

Shian-Yi Chiou, Taipei, TW;

Assignee:

Development Center for Biotechnology, Taipei, TW;

Attorney:

Liang Legal Group, PLLC

Primary Examiner:

Brenda L Coleman

Int. Cl.
CPC ...
A61K 31/44 (2006.01); A61K 31/498 (2006.01); A61P 35/00 (2006.01); C07D 241/40 (2006.01); C07D 241/44 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 241/52 (2006.01); C07D 401/14 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); C07D 401/04 (2006.01); C07D 413/12 (2006.01); C07D 403/04 (2006.01); C07D 405/12 (2006.01); C07D 409/12 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61P 35/00 (2018.01); C07D 241/44 (2013.01); C07D 241/52 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01);
Abstract

A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

Find Patent Forward Citations

Peng, Shao-Zheng. (2020). Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors (U.S. Patent No. 10689362). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10689362

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…